Synthesis and Anti-proliferative Activity of Substituted-Anilinoquinazolines and Its Relation to EGFR Inhibition

 

 Buy Article Permissions and Reprints

Abstract

4-Anilinoquinazoline is a privileged scaffold in developing small molecule inhibitors of tyrosine kinases (TK) especially epidermal growth factor receptor (EGFR). 2 series belonging to 3'-substituted-4-anilinoquinazoline scaffold were synthesized and screened in vitro on isolated and a breast cancer cell line. The research aims at exploring the activity of compounds having diverse substituents at 3' position of the aniline moiety. Generally, the meta-substituted-anilinoquinazolines exhibited significant inhibitory activity against isolated enzyme as well as MCF-7 cancer cell line. For instance, compound 10b inhibited >99% of EGFR activities at 10 µM concentration. 6 of the tested compounds exhibited range of anti-proliferative activity below 10 µM potency. In particular, compounds 6e and 10b displayed the highest activity among the tested compounds with IC₅₀ values equal to 8.6 and 4.84 µM, respectively. Structure-based tools were utilized to rationalize EGFR-TK binding of compound 10b since it is the most active compound in the enzyme inhibition test.

^* These authors contributed equally to this work.

• References

• 1 Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-365
  CrossrefPubMedGoogle Scholar
• 2 Li R, Stafford JA. Kinase Inhibitor Drugs. 1^st ed. Hoboken, New Jersey: John Wiley & Sons; 2009
  CrossrefGoogle Scholar
• 3 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-134
  CrossrefPubMedGoogle Scholar
• 4 Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006; 5: 2820-2826
  CrossrefPubMedGoogle Scholar
• 5 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39
  CrossrefPubMedGoogle Scholar
• 6 Cataldo VD, Gibbons DL, Pérez-Soler R et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-955
  CrossrefPubMedGoogle Scholar
• 7 Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-289
  CrossrefPubMedGoogle Scholar
• 8 Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer – search and destroy. Eur J Cancer 2006; 42: 17-23
  CrossrefPubMedGoogle Scholar
• 9 Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. Int J Clin Exp Pathol 2011; 4: 403-409
  PubMedGoogle Scholar
• 10 Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
  CrossrefPubMedGoogle Scholar
• 11 Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311
  CrossrefPubMedGoogle Scholar
• 12 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774
  CrossrefPubMedGoogle Scholar
• 13 Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31: 2332-2348
  CrossrefPubMedGoogle Scholar
• 14 Cruz-López O, Conejo-García A, Núñez MC et al. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Curr Med Chem 2011; 18: 943-963
  CrossrefPubMedGoogle Scholar
• 15 Cumming JG, McKenzie CL, Bowden SG et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2004; 14: 5389-5394
  CrossrefPubMedGoogle Scholar
• 16 Rewcastle GW, Denny WA, Bridges AJ et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995; 38: 3482-3487
  CrossrefPubMedGoogle Scholar
• 17 Thompson AM, Bridges AJ, Fry DW et al. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1995; 38: 3780-3788
  CrossrefPubMedGoogle Scholar
• 18 Abouzid K, Shouman S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg Med Chem 2008; 16: 7543-7551
  CrossrefPubMedGoogle Scholar
• 19 Kamath S, Buolamwini JK. Targeting EGFRand HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 2006; 26: 569-594
  CrossrefPubMedGoogle Scholar
• 20 Heindel ND, Brodof TA, Kogelschatz JE. Cyclization of amine-acetylene diester adducts. Modification of the Conrad-Limpach method. J Heterocycl Chem 1966; 3: 222-223
  PubMedGoogle Scholar
• 21 Althuis TH, Hess HJ. Synthesis and identification of the major metabolites of prazosin formed in dog and rat. J Med Chem 1977; 20: 146-149
  CrossrefPubMedGoogle Scholar
• 22 Jin Y, Li H-Y, Lin L-P et al. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Bioorg Med Chem 2005; 13: 5613-5622
  CrossrefPubMedGoogle Scholar
• 23 Tsou H-R, Mamuya N, Johnson BD et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J Med Chem 2001; 44: 2719-2734
  CrossrefPubMedGoogle Scholar
• 24 Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst 1990; 82: 1107-1112
  CrossrefPubMedGoogle Scholar
• 25 Konecny GE, Pegram MD, Venkatesan N et al. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Res 2006; 66: 1630-1639
  CrossrefPubMedGoogle Scholar
• 26 Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-46272
  CrossrefPubMedGoogle Scholar
• 27 Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-227
  CrossrefPubMedGoogle Scholar
• 28 Griera R, Armengo M, Reyes A et al. Synthesis and pharmacological evaluation of new cysLT₁ receptor antagonists. Eur J Med Chem 1997; 32: 547-570
  CrossrefPubMedGoogle Scholar
• 29 Brancaccio G, Lettieri G, Viterbo R. Orientation studies in the coumaran series. Revised structure of the nitration product of 5-acetamido-2-methylcoumaran via the elucidation of the Claisen rearrangement of m-acetoamidophenyl allyl ether. Eur J Org Chem 1972; 38: 831-832
  PubMedGoogle Scholar
• 30 Dietrich SW, Smith RN, Fukunaga JY et al. Dihydrofolate Reductase Inhibition by 2,4-Diaminotriazines: A Structure-Activity Study. Arch biochem biophys 1979; 194: 600-611
  CrossrefPubMedGoogle Scholar